Furthermore, Hua et al., employing digital PCR, demonstrated the potential of the increased methylation of GRHL2 in AML patients as a biomarker for prognosis prediction and treatment response monitoring [28]. The gene discussed is GRHL2; the disease is acute myeloid leukemia.